The pharmaceutical industry is certainly no stranger to cyber-attacks. Merck & Co., Inc.'s 2017 'NotPetya' cyberattack is still looming large over the industry, as the legal ramifications - including Merck's $1.4bn insurance claim – continue into 2023. (Also see "Merck Cyberattack Recovery: Congress Scrutinizes Manufacturing Problems" - Pink Sheet, 21 September, 2017.)
More recently, AstraZeneca PLC is in the spotlight for a data breach which saw credentials for one of its...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?